SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:4504.
  • 2
    Palella J, Frank J, Delaney KM, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:85360.
  • 3
    Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society, USA panel. JAMA. 1997;277:19629.
  • 4
    Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:14553.
  • 5
    Fauci AS. AIDS in 1996: much accomplished, much to do. JAMA. 1996;276:1556.
  • 6
    Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mortal Wkly Rep. 1998;47:4382.
  • 7
    Bonfanti P, Capetti A, Rizzardini G. HIV disease treatment in the era of HAART. Biomed Pharmacother. 1999;53:93105.
  • 8
    Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:817.
  • 9
    Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:11635.
  • 10
    Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:30711.
  • 11
    Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:113541.
  • 12
    Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:230515.
  • 13
    Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:47480.
  • 14
    Sorvillo F, Kerndt P, Odem S, et al. Use of protease inhibitors among persons with AIDS in Los Angeles County. AIDS Care. 1999;11:14755.DOI: 10.1080/09540129948045
  • 15
    Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J AIDS. 2000;23:17883.
  • 16
    Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:166570.
  • 17
    Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:635.
  • 18
    Bayer R & Stryker J. Ethical challenges posed by clinical progress in AIDS. Am J Public Health. 1997;87:1599602.
  • 19
    Van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:2904.
  • 20
    Malow RM, McPherson S, Kilmas N, et al. Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Alcohol Drug Abuse. 1998;49:10214.
  • 21
    Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14:26773.DOI: 10.1046/j.1525-1497.1999.00334.x
  • 22
    Gordillo V, Del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:17639.DOI: 10.1097/00002030-199909100-00021
  • 23
    Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:12433 Mar.
  • 24
    Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J AIDS. 1999;21:1149.
  • 25
    Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J AIDS. 1998;18:117225.
  • 26
    Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS. 1998;12:230511.
  • 27
    Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13:1099107.DOI: 10.1097/00002030-199906180-00014
  • 28
    Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15:8417.
  • 29
    Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:16773.
  • 30
    Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res. 1995;30:593614.
  • 31
    Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med. 1994;154:11217.
  • 32
    Center for Medicaid and State Operations. Medicaid and acquired immune deficiency syndrome (AIDS) and human immunodeficiency virus (HIV) infection. http://www.hcfa.gov/medicaid/obs11.htm , April 2000.
  • 33
    Berk ML & Schur CL. Access to care: how much difference does Medicaid make? Health Aff (Millwood). 1998;17:16980.
  • 34
    Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med. 2000;132:30611.
  • 35
    Regenstein M & Anthony SE. Medicaid managed care for persons with disabilities. Economic and Social Research Institute. August 1998. http://newfederalism.urban.org/html/occa11.html#medi .
  • 36
    Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:91125.DOI: 10.1097/00005650-200009000-00005
  • 37
    Fasciano NJ, Cherlow AL, Turner BJ, Thornton CV. Profile of Medicare beneficiaries with AIDS: application of an AIDS casefinding algorithm. Health Care Financ Rev. 1998;19:1938.
  • 38
    Sambamoorthi U, Collins S, Crystal S. Characteristics of dually-eligible Medicaid beneficiaries. Health Soc Policy. in press.
  • 39
    Merzel C, Crystal S, Sambamoorthi U, Karus D, Kurland C. New Jersey's Medicaid waiver for acquired immunodeficiency syndrome. Health Care Financ Rev. 1992;13:2744.
  • 40
    Diggle P, Liang KY, Zeger S. Analysis of Longitudinal Data. Oxford and New York: Oxford University Press; 1994.
  • 41
    Kalbfleisch JD & Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, Inc.; 1980.
  • 42
    Aday LA & Anderson RM. The national profile of access to medical care: where do we stand? Am J Public Health. 1984;74:13319.
  • 43
    Bindman AB, Grumbach K, Osmond D, et al. Preventable hospitalizations and access in health care. JAMA. 1995;274:30511.
  • 44
    Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the department of veterans affairs. JAMA. 1994;271:117580.
  • 45
    Whittle J, Conigliaro J, Good CB, Joswiak M. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993;329:6217.
  • 46
    Carlisle DM, Leake BD, Shapiro MF. Racial and ethnic disparities in the use of cardiovascular procedures: associations with types of health insurance. Am J Public Health. 1997;87:2637.
  • 47
    Gornick ME, Eggers PW, Reilly TW, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med. 1996;335:7919.
  • 48
    Satariano ER, Swanson GM, Moll PP. Nonclinical factors associated with surgery received for treatment of early stage breast cancer. Am J Public Health. 1992;82:1958.
  • 49
    Diehr P, Yergan J, Chu J, et al. The influence of race on the use of surgical procedures for treatment of peripheral vascular disease of the lower extremities. Arch Surg. 1995;130:3816.
  • 50
    Center for Disease Control. Fighting HIV/AIDS in African American communities: a growing crisis. http://www.cdc.gov/hiv/pubs/brochure/African-American.pdf ; October 4, 2000.
  • 51
    Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395401.DOI: 10.1046/j.1525-1497.1999.08198.x
  • 52
    Kitahata MM, Koepseli TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:7016.
  • 53
    Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999Abstract 98.
  • 54
    Centers for Disease Control. AIDS among people aged 50 or older years—U.S., 1991–1996. JAMA. 1998;279:576.
  • 55
    Anderson K & Mitchell JM. Expenditures on services for persons with acquired immunodeficiency syndrome under a medicaid home- and community-based waiver program: are selection effects important? Med Care. 1997;35:42539.DOI: 10.1097/00005650-199705000-00002
  • 56
    Department of Health and Senior Services. Division of AIDS Prevention and Control begins broad initiative to decrease perinatal transmission. AIDSline. 1999;11:12.
  • 57
    Hakki M & Cinti SK. Gaps in pharmacy logs predict poor virologic outcome in HIV-infected patients on highly active antiretroviral therapy. Presented at the annual meeting Michigan Infectious Disease Society, Lansing, Mich, March 2000.
  • 58
    Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:82430.